Literature DB >> 19437348

Corneal lymphangiogenesis: implications in immunity.

Sangita P Patel1, Reza Dana.   

Abstract

The lymphatic system is a network of vessels throughout the body that serves to return lymphatic fluid to the systemic blood circulation and serves as the immune system's highway in the afferent limb of the immune response. This paper reviews the basics of structure, function and development of the lymphatic system. The emphasis is on understanding the role of lymphatics in the cornea as related to angiogenesis and the clinical setting of corneal transplant rejection. The lymphatic system has two main functions: to drain excess extracellular fluid from capillary beds to return to the systemic blood circulation and to capture antigen for presentation to the immune system in the lymphoid compartment (e.g. nodes) connected in parallel to the lymphatic system. The normal cornea is devoid of lymphatic vessels and blood vessels, thus allowing for its unique immune privileged status. Abnormal blood vessel growth into the cornea has been studied for many years, but the study of lymphatic vessels has been hampered until the recent discovery of lymphatic-specific markers. Subsequent studies of vascularized corneas support the presence of lymphatic vessels in the cornea. The growth of new lymphatic (lymphangiogenesis) and blood (hemangiogenesis) vessels in the cornea is closely related to the abrogation of the immune privileged status of the cornea. This review summarizes our current understanding of the parallel development of hemangiogenesis and lymphangiogenesis as related to the mechanisms of immune rejection of corneal transplants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19437348     DOI: 10.1080/08820530902801320

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  19 in total

1.  Relations between lymphangiogenesis and the size of pterygium.

Authors:  Lin Liu; Shi-Qi Ling; Qiao-Li Li; Tao Wang; Hui Ye; Jie-Zhen Yang; Xiu-Hua Jia
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

2.  E-Selectin Mediates Immune Cell Trafficking in Corneal Transplantation.

Authors:  Thomas H Dohlman; Antonio Di Zazzo; Masahiro Omoto; Jing Hua; Julia Ding; Pedram Hamrah; Sunil K Chauhan; Reza Dana
Journal:  Transplantation       Date:  2016-04       Impact factor: 4.939

Review 3.  Immunotherapy for uveal melanoma.

Authors:  Dae Won Kim; Jaime Anderson; Sapna P Patel
Journal:  Melanoma Manag       Date:  2016-05-19

4.  Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium.

Authors:  S Ling; Q Li; H Lin; W Li; T Wang; H Ye; J Yang; X Jia; Y Sun
Journal:  Eye (Lond)       Date:  2012-09-14       Impact factor: 3.775

5.  CXCL10 suppression of hem- and lymph-angiogenesis in inflamed corneas through MMP13.

Authors:  Nan Gao; Xiaowei Liu; Jiayin Wu; Juan Li; Chen Dong; Xinyi Wu; Xiao Xiao; Fu-Shin X Yu
Journal:  Angiogenesis       Date:  2017-06-16       Impact factor: 9.596

6.  Cooperative Effects of Vascular Angiogenesis and Lymphangiogenesis.

Authors:  Tatsuya Osaki; Jean C Serrano; Roger D Kamm
Journal:  Regen Eng Transl Med       Date:  2018-04-23

Review 7.  Influence of immune privilege on ocular tumor development.

Authors:  Kyle C McKenna; Peter W Chen
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

Review 8.  Role of lymphatic vessels in tumor immunity: passive conduits or active participants?

Authors:  Amanda W Lund; Melody A Swartz
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-09-11       Impact factor: 2.673

Review 9.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

10.  Blocking the path of lymphatic vessels.

Authors:  Mihaela Skobe; Reza Dana
Journal:  Nat Med       Date:  2009-09       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.